Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma
-
Published:2023-03
Issue:3
Volume:11
Page:885-895.e13
-
ISSN:2213-2198
-
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
-
language:en
-
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice
Author:
Kritikos Vicky, Harvey Erin S.ORCID, Stevens Sean, Katelaris Constance H., Langton David, Rimmer Janet, Farah Claude S., Gillman Andrew, Hew Mark, Radhakrishna Naghmeh, Thomas Dennis, Gibson Peter G.ORCID, Baraket Melissa, Bardin Philip, Bowden Jeffrey J., Bowler Simon, Chien Jimmy, Chung Li Ping, Grainge Christopher, Harkness Nicholas, Harrington Zinta, Jenkins Christine, Katsoulotos Gregory P., McDonald Vanessa M., Lee Joy, Peters Matthew, Reddel Helen K., Reynolds Paul N., Sivakumaran Pathmanathan, Upham John W., Wark Peter A.B.
Funder
AstraZeneca Sanofi Australia
Subject
Immunology and Allergy
Reference34 articles.
1. Global Asthma Network, The global asthma report. Auckland, New Zealand, 2018. Accessed 8 August 2021. http://globalasthmareport.org/2018/index.html 2. Global strategy for asthma management and prevention: GINA executive summary;Bateman;Eur Respir J,2008 3. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014 4. Diagnosis and treatment of severe asthma: a phenotype-based approach;Jones;Clin Med (Lond),2018 5. Comorbidities in difficult-to-control asthma;Hekking;J Allergy Clin Immunol Pract,2018
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|